HomeCompareVAIAF vs ABBV

VAIAF vs ABBV: Dividend Comparison 2026

VAIAF yields 1.44% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $60.2K in total portfolio value
10 years
VAIAF
VAIAF
● Live price
1.44%
Share price
$51.35
Annual div
$0.74
5Y div CAGR
39.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.2K
Annual income
$7,079.86
Full VAIAF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — VAIAF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVAIAFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VAIAF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VAIAF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VAIAF
Annual income on $10K today (after 15% tax)
$122.59/yr
After 10yr DRIP, annual income (after tax)
$6,017.88/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $15,038.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VAIAF + ABBV for your $10,000?

VAIAF: 50%ABBV: 50%
100% ABBV50/50100% VAIAF
Portfolio after 10yr
$72.3K
Annual income
$15,925.81/yr
Blended yield
22.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

VAIAF
No analyst data
Altman Z
6.7
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VAIAF buys
0
ABBV buys
0
No recent congressional trades found for VAIAF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVAIAFABBV
Forward yield1.44%3.06%
Annual dividend / share$0.74$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR39.3%40.6%
Portfolio after 10y$42.2K$102.3K
Annual income after 10y$7,079.86$24,771.77
Total dividends collected$19.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VAIAF vs ABBV ($10,000, DRIP)

YearVAIAF PortfolioVAIAF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,901$200.91$11,550$430.00$649.00ABBV
2$11,949$285.12$13,472$627.96$1.5KABBV
3$13,192$406.88$15,906$926.08$2.7KABBV
4$14,701$584.82$19,071$1,382.55$4.4KABBV
5$16,578$848.40$23,302$2,095.81$6.7KABBV
6$18,984$1,245.57$29,150$3,237.93$10.2KABBV
7$22,170$1,856.91$37,536$5,121.41$15.4KABBV
8$26,545$2,823.13$50,079$8,338.38$23.5KABBV
9$32,804$4,400.64$69,753$14,065.80$36.9KABBV
10$42,180$7,079.86$102,337$24,771.77$60.2KABBV

VAIAF vs ABBV: Complete Analysis 2026

VAIAFStock

Vaisala Oyj engages in the weather and environmental, and industrial measurement business serving weather related and industrial markets. The company's products include industrial measurement systems, such as HVAC and indoor air meters, industrial transmitters, power transformer monitoring systems, probes and OEM modules, handheld meters, in-line process refractometers, biogas monitoring systems, liquid measurement systems, and viewLinc continuous monitoring systems. It also provides weather and environmental solutions, such as automatic weather stations, radiosondes and sounding systems, weather and environmental sensors, weather radars, wind lidars, visibility and present weather sensors, ceilometers, lightning sensors, air quality sensors, and road state sensors, as well as pressure, temperature, and humidity sensors; and operates an online store. In addition, the company offers maintenance, calibration and repair, and modernization services, as well as extended warranties and data-based solutions. Vaisala Oyj serves various industrial customers, including data centers, chemicals and allied products, fuel cells, power transformers, semiconductors, automotive, cleanrooms, HVAC and indoor air, warehouses, battery manufacturing, compressed air, life sciences and pharmaceutical, sugar, sweeteners, biogas, and research facilities and metrology; pulp, paper, and wood; food, beverages, and agriculture; and oil and gas refineries, and petrochemicals. It also serves weather-dependent markets mainly meteorology, ground transportation, aviation, maritime, renewable and wind energy, and urban weather and environment. The company has operations in Europe, the Middle East, Africa, North and South Americas, and the Asia Pacific. Vaisala Oyj was founded in 1936 and is headquartered in Vantaa, Finland.

Full VAIAF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this VAIAF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VAIAF vs SCHDVAIAF vs JEPIVAIAF vs OVAIAF vs KOVAIAF vs MAINVAIAF vs JNJVAIAF vs MRKVAIAF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.